Key statistics dashboard for Perspective Therapeutics, Inc. (CATX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Stock Data
| Price | $2.88 |
| Market Cap | $328M |
| Enterprise Value | $263.4M |
| Beta | 1.87 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.84 |
| Price / Book | 0.65 |
| P/S | 892.74 |
| EV/EBITDA | -2.27 |
| EV/Sales | 719.67 |
| EV/FCF | -2.17 |
| P/FCF | -2.70 |
| Earnings Yield | -58.42% |
| FCF Yield | -39.36% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -419.40% |
| EBIT Margin | -32546.45% |
| EBITDA Margin | -31750.82% |
| Operating Margin | -34216.39% |
| Net Margin | -31812.57% |
| Return on Equity | -41.56% |
| Return on Assets | -29.70% |
| Return on Invested Capital | -34.94% |
| Return on Capital Employed | -35.23% |
Financial Health
| Current Ratio | 6.61 |
| Quick Ratio | 6.61 |
| Cash Ratio | 1.33 |
| Debt / Equity | 0.01 |
| Debt / Assets | 1.01% |
| Net Debt / EBITDA | 0.38 |
| Interest Coverage | -410.60 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 4.39 |
| Cash per share | 3.21 |
| FCF per share | -1.64 |
| Tangible Book Value per share | 3.85 |
| Dividend per share | 0.00 |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks